Cipla gains 3% on USFDA's final approval for Lanreotide injection
newsdepo.com
ICICI Securities remains positive on Cipla's calibrated approach of focusing more on branded products and core therapies across the worldCipla gains 3% on USFDA's final approval for Lanreotide injection
ICICI Securities remains positive on Cipla's calibrated approach of focusing more on branded products and core therapies across the world Read more